FR2248851A1 - Anti-inflammatory substance from blood - produced by gel filtration of serum or plasma - Google Patents

Anti-inflammatory substance from blood - produced by gel filtration of serum or plasma

Info

Publication number
FR2248851A1
FR2248851A1 FR7435859A FR7435859A FR2248851A1 FR 2248851 A1 FR2248851 A1 FR 2248851A1 FR 7435859 A FR7435859 A FR 7435859A FR 7435859 A FR7435859 A FR 7435859A FR 2248851 A1 FR2248851 A1 FR 2248851A1
Authority
FR
France
Prior art keywords
pref
inflammatory
prodt
serum
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7435859A
Other languages
French (fr)
Other versions
FR2248851B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Development Corp UK
Original Assignee
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB50037/73A external-priority patent/GB1484131A/en
Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK
Publication of FR2248851A1 publication Critical patent/FR2248851A1/en
Application granted granted Critical
Publication of FR2248851B1 publication Critical patent/FR2248851B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

New anti-inflammatory matl. is produced by subjecting serum, plasma or a suitable fraction thereof to ultrafiltration followed by gel-filtration (pref. using a crosslinked dextran), then eluting from the gel a fraction displaying anti-inflammatory activity in the carrageenin rat-paw oedema test. The elution is pref. effected with an aq. medium of low ionic strength (pref. distilled water). The starting matl. is pref. obtd. from human or bovine blood. The prodt. should be substantially free from prodts. of mol.wt. >1,000. The prodt. is suitable for the treatment of rheumatic states and other inflammatory disorders. It is hypothesised that the prodt. is the natural 'protecting factor' which conventional anti-inflammatory agents displace from serum proteins.
FR7435859A 1973-10-26 1974-10-25 Anti-inflammatory substance from blood - produced by gel filtration of serum or plasma Granted FR2248851A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB50037/73A GB1484131A (en) 1973-10-26 1973-10-26 Anti-inflammatory substances
GB3577874 1974-08-14

Publications (2)

Publication Number Publication Date
FR2248851A1 true FR2248851A1 (en) 1975-05-23
FR2248851B1 FR2248851B1 (en) 1978-07-28

Family

ID=26262856

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7435859A Granted FR2248851A1 (en) 1973-10-26 1974-10-25 Anti-inflammatory substance from blood - produced by gel filtration of serum or plasma

Country Status (4)

Country Link
JP (1) JPS5082214A (en)
DE (1) DE2450913A1 (en)
FR (1) FR2248851A1 (en)
NL (1) NL7413874A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3219248A1 (en) * 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden METHOD FOR OBTAINING CELL-BREATHING ACTIVE INGREDIENTS FROM CALF BLOOD
US4956349A (en) * 1983-10-27 1990-09-11 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
CN112315863B (en) * 2020-11-10 2021-12-03 山东百奥生物医药有限公司 Composition for relieving pain and heat sensation in photoelectricity operation and preparation method and application thereof

Also Published As

Publication number Publication date
FR2248851B1 (en) 1978-07-28
JPS5082214A (en) 1975-07-03
NL7413874A (en) 1975-04-29
DE2450913A1 (en) 1975-04-30

Similar Documents

Publication Publication Date Title
Agrawal et al. Physical and chemical characterization of concanavalin A, the hemagglutinin from jack bean (Canavalia ensiformis)
DE19975031I2 (en) Use of 4-aminosalicyl acid as an anti-inflammatory agent.
GB1460607A (en) Isolation of coagulation factors from biological material
DE3484616D1 (en) ENZYME-RESISTANT IMMUNOMODULATIVE PEPTIDES.
EP0229654A3 (en) Treatment of non-acne inflammatory and infectious dermatoses
Mann et al. The molecular weights of bovine thrombin and its primary autolysis products
KR900002795A (en) Hybrid protein C constructs and their preparation
Broekmans et al. Prevalence of protein C (PC) and protein S (PS) deficiency in patients with thrombotic disease
DE69329652D1 (en) EFFECTS OF ACTIN FILMS ON THE STRUCTURE AND LYSIS OF FRIBRINGER ISLANDS
AU567747B2 (en) Early detection of mammalian pregnancy
FR2248851A1 (en) Anti-inflammatory substance from blood - produced by gel filtration of serum or plasma
ES8704184A1 (en) Dna sequences, recombinant dna molecules and processes for producing human lipocortin-like polypeptides.
Takagi et al. Polypeptide chain involved in the cross-linking of stabilized bovine fibrin
Cann Effect of binding of ions and other small molecules on protein structure. VII. The role of aliphatic acid binding and of convection in the electrophoresis of serum albumin at low pH
Paschke et al. Multiple forms of 2-deoxy-D-glucoside-2-sulphamate sulphohydrolase from human placenta
JPS5598196A (en) Fractionation of fibrinogen or its constituents and their use
SE8600987D0 (en) PROCEDURE FOR PREPARING A PROTEIN CONCENTRATE FROM WHOLE BLOOD
WO1995021916A3 (en) Pp32: a newly identified cd45-associated protein
FR2234900A1 (en) Substance for treatment of liver damage - prepd from a protein broth
Mesrob et al. PURIFICATION OF MILK‐CLOTTING PROTEASE FROM BACILLUS MESENTERICUS STRAIN 76
JPS55115856A (en) Active polypeptide and its preparation
GB1293483A (en) Orgotein purification process
Kotkes et al. New approaches to the characterization and isolation of migration inhibitory factor (MIF)
Bouma et al. Characterization of human protein S
IT1045649B (en) Substance for treatment of liver damage - prepd from a protein broth

Legal Events

Date Code Title Description
ST Notification of lapse